NCT04146610Unknown1 期
A Phase Ia, Multicenter, Open and Dose-increasing Study of DP303c to Evaluate the Safety , Pharmacokinetics, Immunogenicity and Antitumor Activity of Subjects With HER2-Positive Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2019年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Maximal Tolerance Dose (MTD) of Dp303c
研究概览
简要总结
A phase Ia, multicenter, open and dose-increasing study of DP303c to evaluate the safety , pharmacokinetics, immunogenicity and antitumor activity of subjects with HER2-positive advanced solid tumors.
详细描述
Dose escalation study: Primary purpose: To investigate the safety and tolerability of DP303c in subjects with HER2-positive advanced solid tumors . Secondary purpose:1. To characterize the pharmacokinetics(PK) profile of DP303c;2. To assess the preliminary anti tumor activity of DP303c; 3. To characterize immunogenicity of DP303c.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntary agreement to provide written informed consent；
- •Aged 18 to 75 years, both male and female;
- •Patients with advanced solid tumors diagnosed by histology and / or cytology, confirmed to be HER2 positive by pathological examination, unable to accept or have no standard treatment, failure of standard treatment (disease progress or treatment without remission after treatment) or intolerable patients; HER2-positive is defined as IHC 2+ and ISH positive or IHC 3+； IHC scores of breast cancer and gastric cancer are based on their respective standards, while IHC scores of other cancers are based on the scoring standards of breast cancer；
- •The ECOG performance status is 0 to 1,and the expected survival time is more than 3 months；
- •Subjects must have laboratory values within the limits described below:
- •ANC ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin ≥9 g/dL Serum creatinine within normal limits OR creatinine clearance ≥60 mL/minute Serum total bilirubin ≤1.5 x ULN (up to 3 x ULN in subjects with Gilbert's syndrome) AST (SGOT) and ALT (SGPT) ≤2.5 x ULN (OR ≤5 X ULN for subjects with liver metastases) PT/INR and APTT ≤1.5 x ULN
- •According to the RECIST v1.1 standard, there must be a measurable lesion at the base line；
- •WOCBP must have a negative pregnancy test prior to study entry；
- •WOCBP and male subjects must agree to use adequate contraception from study entry through at least 12 weeks after the last dose of study drug (see Appendix 5)；
- •A washout period is required for subjects who have recently received systemic antitumor therapy. The period prior to the subject's planned first dose of DP303c must be either at least 28 days or 5 half-lives, whichever is shorter. Antitumor therapy includes chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy (except local radiotherapy for pain relief, 14 days after treatment).
排除标准
- •Pregnant or breastfeeding women；
- •Refusal to use effective methods of contraception (see inclusion criteria for details)；
- •Not recovered from AEs caused by previous drugs or radiotherapy (reference NCI CTCAE 5.0, ≤Grade 1 or at baseline), with the exception of alopecia；
- •History of cardiac dysfunction with LVEF <40% while on trastuzumab therapy；
- •Subjects with a history of allergy to any components(tratozumab analogues, MMAE, sodium citrate dihydrate, citrate monohydrate, polysorbitol 20 and sucrose, etc.) of DP303cand those who researchers consider to be more serious；
- •A history of central nervous system (CNS) metastases or epilepsy, asymptomatic or stable, and not requiring treatment at least 4 weeks before study therapy began；
- •Active lung infection or pneumonitis or a history of non-infectious interstitial lung disease；
- •Requires supplemental oxygen；
- •History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia. Subjects who have the following types of cardiac impairment at the time of enrollment:
- •New York Heart Association class III or IV heart disease Uncontrolled angina, congestive heart failure, or myocardial infarction within 6 months prior to enrolment An LVEF by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan <50% or below the lower limit of normal for the institution QT interval prolongation (>450 ms in males, >470 ms in females),QT interval correction (QTcF) was corrected by Fridericia formula
- •In the first 90 daysof the study, Cumulative anthracycline dose ≥360 mg/m2 doxorubicin or equivalent；
- •Peripheral neuropathy ≥Grade 2 or greater (NCI CTCAE v 5.0)；
- •12.Non-manageable electrolyte imbalances including hypokalemia, hypocalcemia, or hypomagnesemia (≥Grade 2 or greater based on NCI CTCAE v 5.0)；
- •Any uncontrollable intercurrent illness, infection, or other conditions that could limit study compliance or interfere with assessments；
- •Serologic status reflecting active hepatitis B or C infection；
- •Subjects with immunodeficiency, including HIV positive；
- •Patients were treated with CYP3A inhibitors within 14 days of the first dose (drugs that increased specific CYP substrate AUC ≥ 5 times, such as Mibefradil, verapamil, diltiazem, nefazodone, clarithromycin, Telithromycin, Troleandomycin, Erythromycin, fluconazole, itraconazole, ketoconazole, Posaconazole,VoriconazoleTablets，Elvitegravir，indinavir，lopinavir， Nelfinavir，Ritonavir，Saquinavir， Boceprevir，Incivo，telaprevir，Conivaptan，idelalisib) or strong CYP3A inducers (Avasimibe, phenobarbital, phenytoin, carbamazepine,Rifampicin, rifabutin,enzalutamide, mitotane, Hypericum perforatum )；
- •Other serious or uncontrollable diseases or conditions that may affect the assessment of the primary endpoint or that the investigator considers to be at risk for participants participating in this study.
研究组 & 干预措施
Dp303c
Experimental
Multiple dose grouping
干预措施: an antibody drug conjugate (Drug)
结局指标
主要结局
Maximal Tolerance Dose (MTD) of Dp303c
时间窗: The first treatment cycle 21 days
The dose level in which \>= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.
次要结局
- Time of peak plasma concentration (Tmax)(approximately 2 years)
- Maximum concentration (Cmax) of DP303c(approximately 2 years)
- Area under the plasma concentration time curve (AUC) of DP303c(approximately 2 years)
- Overall response rate (ORR)(approximately 2 years)
- Duration of Response (DoR)(approximately 2 years)
- Immunogenicity (anti-drug antibody ADA)(approximately 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Non-small Cell Lung CancerNCT05668988Dizal Pharmaceuticals324
已完成
1 期
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or IntolerableNon-Hodgkin's Lymphoma, Solid CancersNCT00876122Genentech, Inc.60
已完成
1 期
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast CancerBreast NeoplasmsNCT02718144Pantarhei Oncology B.V.12
已完成
1 期
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate CancerCastrate Resistant Prostate Cancer (CRPC)NCT00868595Bellicum Pharmaceuticals18
招募中
1 期
PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesCD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesNCT05170568PersonGen BioTherapeutics (Suzhou) Co., Ltd.22